以嶺藥業和振東製藥連續兩日漲停 連花清瘟治療新冠獲多國認可
格隆匯4月15日丨連花清瘟治療新冠肺炎相繼獲多國認可,A股市場僅有的兩隻連花清瘟概念股已連續兩日漲停。其中,生產連花清瘟的以嶺藥業連續兩日漲停報34.45元,創歷史新高價,年內累漲177%;2月曾在互動平台上表示有“連花清瘟膠囊”所需大部分藥材的振東製藥連續兩日漲停報6.66元,創去年9月以來新高,年內累漲37%。
昨日午間,以嶺藥業發公告稱,收到國家藥品監督管理局下發的《藥品補充申請批件》,增加了連花清瘟膠囊“在新型冠狀病毒肺炎的常規治療中,可用於輕型、普通型引起的發熱、咳嗽、乏力”的功能審批。這意味着,連花清瘟膠囊在疫情期間的救治臨牀實踐正式被官方承認。
據悉,以嶺藥業已將其出口到加拿大、羅馬尼亞、印度尼西亞、莫桑比克、巴西、泰國等地。今日,中國工程院院士、天津中醫藥大學校長張伯禮稱,泰國已經給連花清瘟頒佈許可證,可以在泰國銷售,法國也準備用連花清瘟做新冠肺炎治療的臨牀研究。不過,昨晚以嶺藥業發公告提醒稱連花清瘟膠囊在已獲上市許可國家/地區銷售收入佔營收比重較低。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.